中国药物警戒 ›› 2013, Vol. 10 ›› Issue (3): 168-171.

• 药械安全性研究 • 上一篇    下一篇

25例伊立替康治疗晚期肠癌致不良反应的分析

张晓光,张侠   

  1. 安徽医科大学北京军区总医院临床学院肿瘤科,安徽合肥 230032
  • 收稿日期:2012-11-06 修回日期:2016-03-09 出版日期:2013-03-08 发布日期:2016-03-09
  • 通讯作者: 张侠,女,主任医师,研究生导师。 E-mail:zxlc@hotmail.com
  • 作者简介:张晓光,女,在读硕士,恶性肿瘤的诊治。

Analysis of 25 Cases of Adverse Reactions Induced by Inirotecan in Advanced Colorectal Cancer Patients

ZHANG Xiao-guang, ZHANG Xia   

  1. 1.Department of Oncology, General Hospital of Beijing Military Region, Clinical School of Anhui Medical University, Beijing 100700, China
  • Received:2012-11-06 Revised:2016-03-09 Online:2013-03-08 Published:2016-03-09

PDF (PC)

392

摘要： 目的 研究化疗药物伊立替康致不良反应的相关危险因素,提高伊立替康的临床应用安全性,扩大其临床应用范围。方法 收集2011～12月至2012～10月我院肿瘤科联合伊立替康方案化疗的大肠癌患者,对其不良反应进行分析。利用SPSS 17.0 统计软件进行Fisher 精确检验,分析患者不同临床参数与不良反应的关系。结果 消化道反应总发生率为72%,骨髓抑制总发生率为56%,严重的Ⅲ～Ⅳ度血液学毒性12%,迟发型腹泻总发生率为40%,较严重的Ⅲ度发生率为4%,无严重的Ⅳ度腹泻,占腹泻总发生率的10%。急性胆碱能发生率为16%。腹泻的危险因素为具有长期吸烟饮酒史。结论 伊立体康的不良反应较为常见,而严重的骨髓抑制和迟发型腹泻（Ⅲ～Ⅳ度）发生率较低。发生腹泻的时间大约在用药后4～6 天。具有长期吸烟饮酒史的患者发生腹泻的风险较高,对于这部分患者应加强戒烟戒酒的宣传,继而达到用药安全性。

关键词: 伊立替康, 大肠癌, 不良反应

Abstract: Objective To study the relative risk factors of adverse reactions for improving the application security and expanding the range of irinotecan. Methods Patients were collected and analyzed on adverse reactions in the oncology of our hospital from December 2011 to October 2012, who are using irinotecan combination chemotherapy.Fisher accurate inspection was adopted in SPSS17.0, and analyzed the relations between different kinds of clinical parameters with adverse reactions. Results The incidence of nausea and vomiting was 64.00%. The incidence of severe nausea and vomiting (Ⅲdegrees) was 8.00%.The incidence of bone marrow suppression was 56.00%. Severe bone marrow suppression(above Ⅲdegrees) incidence was 12.00%. Delayed diarrhea incidence was 40.00%. Severe diarrhea (Ⅲdegrees) incidence was 4.00%, no more serious diarrhoea(Ⅳdegree).Acute cholinergic syndrome incidence was 16.00%. Long-term smoking and alcohol drinking history were risk factors of diarrhea. Conclusion The adverse reactions of irinotecan are more common, but severe bone marrow suppression and delayed diarrhea (Ⅲ-Ⅳdegree) with low incidence. Delayed diarrhea occurred around the time of 4～6 days after medication. The patients had delayed diarrhea occurred at higher risk with a long history of cigarette smoking and alcohol drinking. This part of patients should be reinforced of cigarette and alcohol abstinence promotion to achieve the safety.

Key words: Irinotecan, colorectal cancer, adverse reactions

中图分类号: